DDInter1147 DDInter1806
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter . A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects .
Tildrakizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Tildrakizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Tildrakizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Human adenovirus e serotype 4 strain cl-68578 antigen
Tildrakizumab {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Tildrakizumab {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Tildrakizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Tildrakizumab may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Tildrakizumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live